Virpax Pharmaceuticals, Inc. - Common Stock (VRPX)
0.1820
-0.0079 (-4.16%)
Virpax Pharmaceuticals Inc is a pharmaceutical company focused on developing innovative delivery systems for medications, primarily targeting pain management and therapeutic solutions
The company is dedicated to transforming the way drugs are administered, using advanced technologies to enhance efficacy and patient experience. By leveraging its proprietary drug delivery platforms, Virpax aims to address unmet medical needs and improve the overall effectiveness of treatments. Their robust pipeline includes various candidates tailored for different therapeutic areas, reflecting a commitment to advancing healthcare through cutting-edge medical research and development.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose Range Finding study for Probudur.
